AMS BioteQ was invited to exhibit at the inaugural Japan Pharmaceutical Exhibition.

鉅亨網

The Japan Pharmaceutical Industry Exhibition (CPHI JAPAN) was grandly held from April 17th to 19th this year (2024). It is the largest and most international annual pharmaceutical industry exhibition in Japan, with over 400 pharmaceutical raw material, equipment, and service suppliers participating each year. AMS BioteQ (stock code: 6864-TW), invited by the National Science Council Southern Taiwan Science Park Administration, appeared on stage in a themed pavilion to showcase the research achievements in "Antiviral Herbal Medicine" and "Anti-tumor Novel Therapy," targeting the precise health market.

AMS BioteQ focused on pharmaceutical research in this exhibition, utilizing its exclusive biotechnology extraction technology ExtrO to launch two major thematic projects: "Antiviral Herbal Medicine AMS-2140," a small molecule drug extracted from natural plants, confirmed through animal experiments to effectively combat various emerging viruses with low toxicity, representing the future star of herbal medicine; and "Perfect Compound - AMS Premium Vitality Drink," made from a variety of precious medicinal materials, long-term consumption of which can regulate physiological functions and provide daily vitality. Recently, AMS BioteQ also collaborated with E-DA Cancer Hospital to conduct human clinical trials, clinically proving its effectiveness in assisting cancer patients and significantly improving their post-operative recovery, making it the best nutritional supplement for cancer patients during treatment.

During the exhibition, the number of visitors was continuous, with an effective visitor rate of up to 50%. In addition to the majority of local visitors from Japan, visitors from China, Hong Kong, Korea, and Southeast Asia accounted for about 30%. Visitors from Southeast Asia mainly came from countries such as India, Thailand, Malaysia, and Singapore. The remaining 10% of visitors came from Europe and South America, such as Switzerland and Chile. Furthermore, the composition of visitors was diverse, including raw material suppliers, pharmaceutical representatives, import and export traders, medical equipment agents, personnel from medical institutions and long-term care facilities, including many high-level decision-makers.

In order to seek more opportunities for cooperation between Taiwanese and Japanese companies, AMS BioteQ also actively participated in the Taiwan-Japan Pharmaceutical Industry Exchange and Matchmaking Meeting organized by the National Science Council Southern Taiwan Science Park Administration on the 18th. At the meeting, AMS BioteQ also demonstrated a high level of research and development capabilities, attracting the attention of many Japanese pharmaceutical-related companies and obtaining opportunities for one-on-one matchmaking, creating more possibilities for business exchanges.

AMS BioteQ showcased two pharmaceutical research achievements and an innovative technology at this meeting, receiving high attention. It also plans to accelerate the application for relevant licenses in Japan this year to quickly seize the Japanese big health market and is expected to bring revenue growth in 2025. During the exhibition, researchers from AMS BioteQ also visited the site to introduce their potential products in detail, showcasing AMS's research and development capabilities in biopharmaceuticals. Through this conference exhibition, the company's innovative products and technologies have opened up new directions in the field of precision health care, attracting high attention from domestic and foreign industries and investors.